497 results about "Immunity response" patented technology

The present invention discloses a strain of Lactobacillus paracasei that simultaneously activates immune regulation and antioxidant pathways to alleviate vaginitis, belonging to the field of microbial technology. The present invention screened and obtained a strain of Lactobacillus paracasei CCFM1316, which has the effect of repairing related symptoms such as immune disorders and oxidative damage caused by vaginitis, specifically embodied in: reducing cellular NF-κB mRNA expression and cell supernatant IL-1β content, improving mouse vaginal immune response, enhancing mouse vaginal antioxidant capacity, improving mouse vaginal pathological manifestations and reducing pathogenic bacteria load. It reduces the mouse vaginal Gardnerella load and improves mouse vaginal pathological manifestations; therefore, Lactobacillus paracasei CCFM1316 has great application prospects in products that improve and repair immune disorders and oxidative damage problems caused by vaginitis.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention discloses preparation and application of dual-network hydrogel. The dual-network hydrogel comprises the following components: (Z1) a spinal cord acellular matrix network DSM formed by self-assembly of a spinal cord acellular matrix dSECM; and (Z2) a metal-polyphenol network MPN formed by coordination of metal ions and polyphenols; wherein the DSM and the MPN are cross-linked through hydrogen bonds to jointly form a double-network structure. DSM provides a microenvironment suitable for cell survival and growth for the dual-network hydrogel and induces stem cells to differentiate into neurons, and MPN provides the dual-network hydrogel with biological effects of inhibiting inflammation and accumulation of reactive oxygen species (ROS). The dual-network hydrogel has the advantages of the two components, the active component neurotrophic factor and the inhibitor loaded on the dual-network hydrogel can regulate and control immune response after SCI, improve neuroinflammation microenvironment and promote nerve repair, and a new strategy is provided for in-situ tissue repair of SCI.

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention provides application of lactobacillus rhamnosus GOLDGUT-M520 or a composition of the lactobacillus rhamnosus GOLDGUT-M520 in preparation of a product for enhancing the immunity of an organism. The lactobacillus rhamnosus GOLDGUT-M520 has the function of enhancing the immunity in both a viable form and an inactivated form of the lactobacillus rhamnosus GOLDGUT-M520. The lactobacillus rhamnosus GOLDGUT-M520 has a good antibacterial capability on escherichia coli and staphylococcus aureus which are pathogenic to intestinal tracts, and is beneficial to enhancing a chemical barrier in an innate immune barrier; the strain can improve the phagocytic activity of macrophages and enhance the innate immune response; the strain can improve the T cell proportion, the B cell proportion and the immune globulin level in mesenteric lymph nodes of immunocompromised mice, and can enhance adaptive immune response. The lactobacillus rhamnosus GOLDGUT-M520 can comprehensively play a role in enhancing immunity, and meanwhile, the inherent immune barrier, the inherent immune response and the adaptive immune response are enhanced.

The present invention belongs to the field of bioelectrode technology, and specifically relates to an injectable soft bioelectrode hydrogel and its preparation method and application. The preparation method includes preparing an E-A complex and preparing a hydrogel. The hydrogel of the present invention is used to prepare an injectable soft bioelectrode, and the hydrogel is directly injected into the target tissue site through a needle to form a flexible and well-adhesive electrical stimulation interface, which significantly improves the accuracy and stability of electrical stimulation. The hydrogel composition principle and preparation method make it easier to regulate and micro-precisely inject according to different human body parts or clinical needs. Implanting the hydrogel into acupuncture points or other specific tissue sites and applying electrical stimulation can effectively avoid local tissue trauma and immune overreaction caused by traditional hard electrodes. For example, for pancreatic cancer, the electrode of the present invention can achieve more controllable and continuous electrical stimulation, and has the potential to regulate local immune response and inflammation levels, providing a safer and more cost-effective new treatment strategy for clinical diagnosis and treatment.

The invention discloses a cell interaction identification method based on cell space transcriptome data, which comprises the following steps: constructing cell pairs according to cell space proximity, and calculating an interaction signal matrix and space information of each pair of cells by combining a ligand-receptor database; then generating cell pair embedding representation by using a graph neural network, calculating the similarity between cell pairs, and calculating the similarity between cells based on a gene expression matrix; updating the similarity matrix through iteration until convergence to obtain a final similarity matrix between cells and between cell pairs; and clustering the similarity matrix, and constructing a cell type and cell pair type model, thereby realizing accurate cell interaction identification. According to the method, space and expression information can be fully utilized, inter-cell heterogeneity and context specificity interaction can be captured, the analysis precision and biological authenticity of a cell communication network are improved, and an effective tool is provided for research on tissue development, disease mechanisms, immune response and the like.

The invention relates to a cationized manganese nano adjuvant as well as a preparation method and application thereof. The cationized manganese nano adjuvant comprises manganous-manganic oxide nano particles and cationized template molecules wrapping the surfaces of the manganous-manganic oxide nano particles, the cationization template molecule is a protein subjected to cationization modification treatment, or a protein fragment thereof, or a polypeptide fragment thereof. Precise regulation and control of surface charges and structures of the manganese nanoparticles are realized through a biomineralization technology, and the key problems of a traditional vaccine adjuvant in the aspects of antigen delivery, immune activation and biocompatibility are effectively solved. The cationized manganese nano adjuvant can efficiently adsorb various antigens to form a stable nano vaccine compound, and congenital immunity and adaptive immunity response of an organism can be remarkably activated; lymph nodes can be effectively targeted, the enrichment degree of antigens in the lymph nodes is improved, and the immune effect is further enhanced; meanwhile, the biotoxicity is low, and the stability is excellent.

The invention belongs to the technical field of genetic engineering, and relates to application of a wheat disease-resistant factor TaCBL4 in prevention and treatment of basal stem rot. A wheat strain capable of overexpressing the wheat disease-resistant factor gene TaCBL4 is obtained by adopting an agrobacterium-mediated method, and the condition that the wheat disease-resistant factor TaCBL4 plays a positive regulation role in the immune response of wheat stem rot resistance is known by comparing the morbidity condition and the fungal biomass condition of a receptor wheat Fielder infected with stem rot pathogens. On the basis, the wheat disease-resistant factor TaCBL4 provided by the invention can be used for creating a stem rot resistant wheat germplasm material, and plays an important role in prevention and treatment of wheat stem rot.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

The invention provides a tulabacillus Tul4 protein trimer, according to the Tul4 protein trimer, an N-terminal natural Loop region of a monomer of the Tul4 protein trimer is used as flexible connection, Tul4 proteins are connected in series to form the trimer Tul4-trimer, the trimer can retain monomer conformation before fusion and fully expose important T cell epitopes of the monomer, an Ad5-Tul4-trimer vector based on type-5 adenovirus is constructed, and the tulabacillus Tul4 protein trimer can be used for preparing the Tul4 protein trimer. According to the present invention, the Tul4 trimer with the high expression can be obtained in the host cell, the Tul4 trimer can induce the efficient specific humoral immune response under the intramuscular injection and nasal drip immune pathway, the latter can induce the strong mucosal immune response, and the Tul4 trimer can be used for preparing the vaccine for preventing the Tul4 infection or the drug for treating the Tul4 infection.

The invention belongs to the field of molecular biology, and particularly relates to application of an OsNiR1 gene to improvement of rice broad-spectrum disease resistance and improvement of rice agronomic traits. The invention provides an application of an OsNiR1 gene, and the application comprises an application in preventing and treating plant diseases and / or enhancing the resistance of plants to pathogenic bacteria, and / or an application in improving agronomic traits of the plants. The amino acid sequence coded by the OsNiR1 gene is as shown in SEQ ID NO. 1, and the CDS sequence of the OsNiR1 gene is as shown in SEQ ID NO. 2. The application proves that OsNiR1 participates in regulating and controlling the immune response pathway of rice to fungal disease rice blast, fungal disease banded sclerotial blight and bacterial disease bacterial leaf blight. Meanwhile, after the strong promoter ubi is adopted for driving, an overexpression material of the OsNiR1 is higher and stronger than a wild plant type, and the tiller number is increased. The invention provides important gene resources and molecular theoretical basis for developing a new variety of broad-spectrum disease-resistant rice.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The application discloses a kind of implant and its preparation method and application, the implant includes material body, metal oxide layer and mixed crystal layer, the mixed crystal layer is located the surface of the metal oxide layer;The metal oxide layer includes metal oxide nanorod array;The metal oxide is selected from zinc oxide, silver oxide or its combination;The mixed crystal layer includes CaP crystal and metal oxide crystal.The implant of the application is sterilized by the bacteriostatic metal ion generated by physical puncture and degradation of metal oxide nanorod, has good antibacterial effect to gram-positive bacteria and gram-negative bacteria, prevents infection;It can also relieve post-implantation inflammatory response, reduce immune response under post-implantation infection, shorten wound healing time.In addition, due to the coating effect of mixed crystal layer on metal oxide layer, the bacteriostatic metal ion is slowly released, the release time is long, and long-lasting antibacterial effect can be achieved, and post-implantation inflammatory response can be reduced.

Vaccine compositions for protecting a subject against diseases caused by viral pathogens of the Picornaviridae family are disclosed. These vaccines comprise nucleic acids encoding the capsid polyprotein (P1 polyprotein) mixed with the viral 3C protease that processes the P1 polyprotein, and encapsulated within nanoparticle carriers. Methods of preventing, reducing, inhibiting, or delaying the symptoms of an infection caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject are provided. Methods of making the vaccines are also described.

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to human CD28, and a second antigen-binding domain that binds specifically to human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention can inhibit the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is convenient and / or therapeutically beneficial.

The application belongs to the technical field of genetic engineering, and relates to application of an immune negative regulatory factor NbELP1 in improving plant disease resistance. NbELP1 The gene is used as a plant immune negative regulatory factor, and negatively regulates early immune response induced by PAMP. NbELP1 Knocking out the gene can effectively improve the disease resistance of plants in response to pathogenic bacteria infection, and does not affect the normal growth of plants. NbELP1 The immune negative regulatory factor gene or its orthologous gene widely exists in various plants and is functionally conservative, is a high-quality gene resource with potential for genetic improvement of disease resistance of various plants, and has great application prospect.

Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The invention discloses a fertilizer for promoting and improving the immunity of plants and a preparation method, and relates to the field of fertilizers. The preparation method comprises the following steps: mixing, smashing and grinding earthworms, eucalyptus leaves, wheat leaves and hawthorn leaves, putting into an ethanol solution, oscillating for 20-24 hours in a shaking table, and centrifugally filtering to obtain an active extracting solution; adding a sodium alginate solution into the suspended bacteria solution and the active extracting solution, and slowly adding carboxymethyl chitosan and a calcium chloride solution; and preparing. According to the invention, the plant growth-promoting rhizobacteria are fixed in the composite hydrogel, and the composite hydrogel can promote colonization of strains at plant root tips and lateral roots so as to regulate deposition of endothelial cell suberite, optimize mineral nutrition balance and abiotic stress response of plants and improve accumulation of auxin at the root tips; meanwhile, an active extracting solution is added into the composite hydrogel, immune response can be activated, and the metabolic activity and antioxidant activity of plants are greatly improved in combination with extracts of other substances.

Provided are methods for inducing immune responses against pathogens in a mammal. The methods comprise administering a single cycle adenovirus (SC-Ad) comprising a nucleic acid sequence encoding an immunogen of said pathogen to said mammal. The SC-Ad is administered by inhalation and infects a cell of said mammal, thereby causing expression of said immunogen leading to the induction of said immune response. New infectious virions are not produced. The methods may be of particular utility in vaccination for respiratory pathogens. Corresponding medical uses of the SC-Ads are also provided.